Wegovy is a new drug that was approved by the FDA in June 2021 for the treatment of obesity in adults. It contains semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone that helps regulate appetite and food intake. Wegovy is administered once a week as a subcutaneous injection [1].

According to a comparison made by UCHealth Today [2], Wegovy is more effective than Ozempic, which is another GLP-1 receptor agonist used for the treatment of obesity. In clinical trials, Wegovy led to an average weight loss of 15% of body weight, while Ozempic led to an average weight loss of 11% of body weight. Moreover, Wegovy has been found to be more effective in reducing cardiovascular events and improving glycemic control in patients with type 2 diabetes.

However, it is important to note that both Wegovy and Ozempic have similar side effects, which include nausea, vomiting, diarrhea, and constipation. In rare cases, they can also cause pancreatitis and kidney damage. Therefore, it is important to discuss the risks and benefits of these drugs with a healthcare provider before starting treatment [3].

In conclusion, based on the provided sources, Wegovy appears to be more effective than Ozempic in terms of weight loss and other health benefits. However, both drugs have similar side effects and should be used under the guidance of a healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/
[3] https://www.drugs.com/medical-answers/mounjaro-wegovy-ozempic-compare-weight-loss-3570898/